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The nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is activated by a large number of xenobiotic and
hypolipidemic compounds called peroxisome proliferator chemicals (PPCs). One agonist of PPARα (WY-14,643) regulates
responses in the mouse liver to chemical stress in part by altering expression of genes involved in proteome maintenance (PM)
including protein chaperones in the heat shock protein (Hsp) family and proteasomal genes (Psm) involved in proteolysis.
We hypothesized that other PPARα activators including diverse hypolipidemic and xenobiotic compounds also regulate PM
genes in the rat and mouse liver. We examined the expression of PM genes in rat and mouse liver after exposure to 7 diﬀerent
PPCs (WY-14,643, cloﬁbrate, fenoﬁbrate, valproic acid, di-(2-ethylhexyl) phthalate, perﬂuorooctanoic acid, and perﬂuorooctane
sulfonate) using Aﬀymetrix microarrays. In rats and mice, 174 or 380PM genes, respectively, were regulated by at least one PPC.
The transcriptional changes were, for the most part, dependent on PPARα, as most changes were not observed in similarly treated
PPARα-null mice and the changes were not consistently observed in rats treated with activators of the nuclear receptors CAR or
PXR. In rats and mice, PM gene expression exhibited diﬀerences compared to typical direct targets of PPARα (e.g., Cyp4a family
members). PM gene expression was usually delayed and in somecases, it was transient. Dose-response characterization of protein
expression showed that Hsp86 and Hsp110 proteins were induced only at higher doses. These studies demonstrate that PPARα,
activated by diverse PPC, regulates the expression of a large number of genes involved in protein folding and degradation and
support an expanded role for PPARα in the regulation of genes that protect the proteome.
1.Introduction
Peroxisome proliferator chemicals (PPCs) are a large class
of structurally heterogeneous pharmaceutical and industrial
chemicals originally identiﬁed as inducers of the size and
number of peroxisomes in rodent livers. The peroxisome
proliferator-activated receptor family is a subset of the
nuclear receptor superfamily and includes three family
members (PPARα, β,a n dγ). The PPARα subtype plays a
dominant role in mediating the eﬀects of hypolipidemic
and xenobiotic PPC in the liver [1]. Activation of PPARα
results in a predictable set of responses in the livers of
rats and mice, including hepatocyte peroxisome prolifera-
tion, hepatomegaly, hepatocyte hyperplasia, and increased
incidence of liver tumors [2]. These responses require a
functional PPARα,s i n c eP P A R α-null mice exposed to the
PPARα agonists WY or bezaﬁbrate lack all of these responses
[3–5]. PPARα controls these phenotypic responses by regu-
lating a large number of genes in the liver including those
involvedin lipidhomeostasis such as fattyacidoxidationand
peroxisome assembly.
Various physical or chemical stressors can produce
disease states in which proteins are damaged or misfolded in
part through increases in oxidative stress. Many endogenous2 PPAR Research
pathways are activated to restore cellular homeostasis,
including stabilization of unfolded proteins to prevent
aggregation as well as removal of damaged or excess
proteins through proteolysis. Stabilization of unfolded pro-
teins is performed by molecular chaperones that assist
in the folding of nascent polypeptides. Many chaperone
genes exhibit increased expression after exposure to a
wide variety of stimuli including chemical exposure or
increased temperatures and are thus called heat shock
(HS) protein (Hsp) genes [6–8]. These proteins play key
roles in a number of human diseases [9] and are essential
for cellular survival under physical or chemical exposure
conditions that increase oxidative stress [10, 11]. Additional
guardians of the proteome include the genes encoding
components of the proteasome. The proteasome carries
out ubiquitin-dependent and -independent proteolysis of
damaged proteins [12]. The 26S proteasome consists of
a 20S core and two 19S regulatory particles containing a
total of 28 subunits. Proteasomal (Psm) gene expression
can be induced by treating cells with proteasomal inhibitors
[13].
There is compelling evidence that PPARα protects multi-
ple tissues from oxidative stress induced by chemical insults
[14]. The hypolipidemic drug and PPC, cloﬁbrate, protects
the liver from damage from the cytotoxicantacetaminophen
in wild-type but not PPARα-null mice [15]. Compared
to wild-type mice, untreated PPARα-null mice or primary
hepatocytes isolated from PPARα-null mice were more
sensitive to carbon tetrachloride-, paraquat- or cadmium-
induced toxicity [16]. The beneﬁcial eﬀects of caloric
restriction in protecting the liver from cytotoxicant-induced
liver injury were shown to depend on PPARα [17]. In the
kidney, PPARα- n u l lm i c ew e r em o r es e n s i t i v et od a m a g e
after ischemia-reperfusion injury [18], and priorexposure of
wild-type mice to PPC reduces the injury [19]. Our previous
microarray studies identiﬁed PM genes regulated by the
PPARα agonist WY-14,643 (WY) including those involved
in protein folding (e.g., Hsp genes) as well as ubiquitin-
dependent and -independent proteolytic processing through
t h ep r o t e a s o m e( e . g . ,Psm genes) [16]. Altered regulation of
these genes by PPC could help to explain why PPC exposure
through PPARα helps to protect tissues from environmental
stressors.
In the present study, we hypothesized that PPARα
activators other than WY also regulate PM genes in the rat
and mouse liver. We examined the expression of PM genes
in rat and mouse liver after exposure to 7 diﬀerent PPC
(WY, cloﬁbrate (CLO), fenoﬁbrate (FENO), valproic acid
(VPA), di-(2-ethylhexyl)phthalate (DEHP), perﬂuorooc-
tanoic acid (PFOA) and perﬂuorooctane sulfonate (PFOS))
using Aﬀymetrix microarrays from published studies. We
show that both therapeutic and environmentally relevant
PPC exposure has a dramatic impact on PM gene expression
intheratandmouseliver.Althoughmostofthechangeswere
PPARα-dependent, there were diﬀerences in their temporal
and dose-dependent regulation compared to typical PPARα
target genes involved in fatty acid oxidation. Our ﬁndings
suggest PPARα is a major regulator of PM genes that have
an impact on stress responses in the liver.
2.Materialsand Methods
2.1. Animal Studies for Chaperone Protein Expression. The
ﬁrst study was carried out at CIIT, Centers for Health
Research, Research Triangle Park, NC utilized wild-type
and PPARα-null male mice 9–12 weeks of age on a mixed
SV129/C57BL/6J background and have been described pre-
viously [20]. Control and treated mice were provided with
NIH-07 rodent chow (Zeigler Brothers, Gardeners, PA) and
deionized, ﬁltered water ad libitum. Lighting was on a 12-
hr light/dark cycle. Wild-type and PPARα-null mice were
given seven daily gavage doses of 0.1% methyl cellulose
control (Sigma Chemical Co., St. Louis, MO), or di-
(2-ethylhexyl)phthalate (DEHP) (1000mg/kg/bw/day) and
sacriﬁced 24hrs after the last dose.
The second study (NTP study number TOX-60) was
carried out at Battelle (Columbus, OH) under a contract
from the National Toxicology Program. Male B6C3F1 mice
at 4–6 weeks of age were obtained from Taconic Farms,
Inc. (Germantown, NY). The feed was NTP-2000 in meal
form (Zeigler Brothers, Inc., Gardners, PA) and the drinking
water was from the City of Columbus municipal supply.
Both feed and water were supplied ad libitum. At 7-8
weeks of age, the mice received in their feed WY at 0, 5,
10, 50, 100, or 500ppm. The mice were euthanized after
6 days of exposure to WY. Portions of the livers were
rapidly snap-frozen in liquid nitrogen and stored at −70◦C
until analysis. All animal studies were conducted under
federal guidelines for the use and care of laboratory animals
and were approved by Institutional Animal Care and Use
Committees.
2.2.Animal Studies Used forMicroarray Analysis. The experi-
ments related to cloﬁbrate- (CLO-) and valproic acid- (VPA-
) treated rats were described in Jolly et al. [21]. Brieﬂy, male
Sprague-Dawley rats (n = 5) were given a single dose of
CLO or VPA at the level of 1,000mg/kg and 2,000mg/kg,
respectively. Animals were killed at 4, 24, and 48hrs after
exposure. Eleven-to-12-week-old male Sprague-Dawley rats
were dosed with 20 or 10mg/kg/day PFOA or PFOS, respec-
tively, in an aqueous solution of 15% Alkamuls EL-620 for 2
daysand sacriﬁced 24hours lateras describedinMartin etal.
[22]. The animal study of fenoﬁbrate (FENO) was described
in Sanderson et al. [23]. Male pure-bred SV129 and PPARα-
null mice (2–6 months of age) on a SV129 background were
used in the experiments. Fenoﬁbrate was given by gavage
(10mg/ml suspension in 0.5% carboxymethyl cellulose).
Animals were sacriﬁced 6 hours after treatment. Four wild-
type and PPARα-null male mice (129S1/SvlmJ wild-type
and PPARα-null) per group (6 months of age) were dosed
by gavage for 7 consecutive days with PFOA (3mg/kg/day)
in distilled water as described in Rosen et al. [24]. At the
end of the dosing period, animals were euthanized by CO2
asphyxiation and liver tissue was collected for preparation of
total RNA.
2.3. Western Blot Analysis. Liver lysates were prepared in
250mM sucrose, 10mM Tris-HCl, pH 7.4, and 1mM EDTAPPAR Research 3
with protease inhibitors (0.2mM phenylmethylsulfonyl ﬂu-
oride, 0.1% aprotinin, 1μg/ml pepstatin, 1μg/ml leupeptin)
as previously described [25]. Fifty μg hepatocyte whole
cell lysate was subjected to 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis followed by transfer to
nitrocellulose membranes. Immunoblots were developed
using primary antibodies against acyl-CoA oxidase (ACO)
(a kind gift from Stefan Alexson, Huddinge University
Hospital, Huddinge, Sweden), HS proteins (Santa Cruz
Biotechnology, Santa Cruz, CA; StressGen, Victoria, B.C.,
Canada) or CYP4A (GenTest, Waltham, MA) and appro-
priate secondary antibodies conjugated with horseradish
peroxidase (Santa Cruz Biotechnology) in the presence of
chemiluminescent substrate ECL (Amersham, Piscataway,
NJ). Blots were quantitated using Gel-Pro (MediaCybernet-
ics, SilverSpring, MD). Most antibodies recognized only one
major band with the expected size. Antibodies to TCP1η
routinely gave 2 bands: a ∼60kDa representing the full-
length protein and a possible fragment of ∼40kDa. In this
study we report the levels of the full-length TCPη and ACO
protein (ACO-A). The expression of ACO-B protein, the
52kDa processed form of ACO-A [26] was also measured.
There were 3 animals per treatment group. Variability is
expressed as standard error of the mean. Means and S.E.
(n = 3) for western data were calculated by Student’s t-test.
The level of signiﬁcance was set at P ≤ .05.
2.4. Analysis of Microarray Data. A summary of the microar-
ray studies is shown in Table 1. The doses selected in these
studies would be expected to elicit close to a maximal
transcriptional response. The raw data ﬁles analyzed in
this project (.cel ﬁles from Aﬀymetrix DNA chips) were
either downloaded from Gene Expression Omnibus (GEO)
or communicated through the original authors. All of the
Aﬀymetrix (Santa Clara, CA) .cel ﬁles were ﬁrst analyzed by
Bioconductor SimpleAﬀy to assess data quality [27]. All .cel
ﬁles passed this QC step. Data (.cel ﬁles) were analyzed and
statistically ﬁltered using Rosetta Resolver version 7.1 soft-
ware(RosettaInpharmatics,Kirkland,WA).Thebackground
correction was done by Resolver’s speciﬁc data processing
pipeline called Aﬀymetrix Rosetta-Intensity Proﬁle Builder.
Statistically signiﬁcant genes were identiﬁed using one-way
ANOVA with a false discovery rate (Benjamini-Hochberg
test) of ≤0.05 followed by a post hoc test (Scheﬀe) for
signiﬁcance. Fold-changevalues<1.5were removed.Asmost
of the experiments in rats used the RG-U34A array, we
compared proﬁles in the RG-U34A annotation ﬁle from
Aﬀymetrix(http://www.aﬀymetrix.com/analysis/index.aﬀx).
We identiﬁed probeset IDs (a total of 8799) on the U34A
chip that exhibited sequence similarity with those on
the RAE230 2 chip using the “good match” comparison
and then built fold-change values for those genes from
the RAE230 2 chip which were altered signiﬁcantly. Heat
maps were generated using Eisen Lab Cluster and Treeview
software (http://rana.lbl.gov/EisenSoftware.htm). A detailed
description of each experiment is available through Gene
Expression Omnibus at the National Center for Biotech-
nology Information at http://www.ncbi.nlm.nih.gov/geo/,a s
accession numbers indicated in Table 1.
PM genes were identiﬁed using the following gene
ontology identiﬁers: 0031072:heat shock protein binding,
0006457:protein folding, 009408:response to heat, 0051085
:chaperone cofactor-dependent protein folding, 0006950:re-
sponse to stress, 0006983:endoplasmic reticulum overload,
0006512:ubiquitin cycle, and 0006511:ubiquitin-dependent
protein catabolic process. A number of proteasome genes
(Psm family) not linked to GO identiﬁers were also included.
3.Results
Our previous experiments indicated that a PPARα agonist
(WY) alters the expression of PM genes in the mouse liver
including those involved in protein folding and protein
degradation [16]. To determine if otherPPARα agonists have
similar activities, we examined transcript proﬁles in rat and
mouse liver after treatment with compounds that possess
PPARα agonist-like activities including three hypolipidemic
compounds (WY, cloﬁbrate (CLO), fenoﬁbrate (FENO)),
an antiepilepsy drug (valproic acid, VPA), and three envi-
ronmentally relevant chemicals (the plasticizer, di-(2-ethyl-
hexyl)phthalate (DEHP) and the surfactant processing aids,
perﬂuorooctanoic acid (PFOA) and perﬂuorooctane sulfo-
nate (PFOS) (Table 1). PM genes were identiﬁed using gene
ontology (GO) identiﬁers (e.g., protein folding; response to
stress including endoplasmic reticulum overload; ubiquitin-
dependent protein catabolic process).
3.1. Altered Expression of Proteome Maintenance Genes in
the Rat and Mouse Liver after Exposure to Diverse PPC.
We examined gene expression in the livers of rats and
mice treated with PPC. In both species, PPC increased
expression of genes known to be regulated by PPARα
includingthoseinvolvedinfattyacidoxidationsuchasCyp4a
familymembers,acyl-CoAoxidase1(Acox1)andperoxisome
assembly genes, for example, Pex11a (Figures 1(a) and 2(a)).
The global expression of all PM genes in the rat and mouse
l i v e ri ss h o w ni nF i g u r e s1(b) and 2(b), respectively. Out
of a total of 288 PM probe sets identiﬁed in the rat, 174
were altered by one or more of the 14 treatment conditions
(Supplemental File 1). Likewise, out of the total of 1597 PM
probe sets examined in the mouse, 382 were altered by one
or more of the 12 treatment conditions (see Supplementary
Material available online at doi:10.1155/2010/727194).
There were a number of similarities exhibited by the
PM genes in both species. First, the altered genes were
dominated by those that were upregulated after exposure.
The upregulated genes outnumbered the downregulated
genes ∼2 to 1. Second, the PM genes exhibited a delay in
altered expression compared to the known direct targets
of PPARα.T h ed i r e c tt a r g e t so fP P A R α were increased as
soon as 4hrs (rat) or 6hr (mouse) after initial exposure. In
contrast, almost none of the PM genes in rats were altered
at 4hrs and some required up to 2 days of exposure before
expression changes were observed. Most of the expression
changes that occurred after WY exposure in the mouse liver
were observed at 5 days but not 6hrs. Third, a number
of PM genes exhibited transient changes compared to4 PPAR Research
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Figure 1: Altered expression of proteome maintenance genes by diverse PPC in rat liver. Male rats were treated with DEHP, VPA, CLO, WY,
PFOA, or PFOS for the indicated times. Hepatic mRNA transcripts were assessed using Aﬀymetrix arrays. Genes involved in PM including
proteinchaperoneswereidentiﬁedasdescribed inSection2.(a)Positivecontrolgenes.(b)ExpressionofallPMgenesalteredbyatleastoneof
the treatments. Genes were clustered using one-dimensionalhierarchical clustering. All genes are foundin the Supplementary Material.Red:
up-regulation; green: down-regulation; black: no change; grey: no data. The intensity scales indicates fold-change due to chemical exposure
relative to controls. Abbreviations: WY: WY-14,643; DEHP: di-(2-ethylhexyl)phthalate; PFOA: perﬂuorooctanoic acid; VPA: valproic acid;
CLO: cloﬁbrate; PFOS: perﬂuorooctane sulfonate.
the constant expression ofthe direct targetsofPPARα. Genes
were induced by DEHP, VPA or CLO at 1 but not 2 days;
in the mouse liver, a subset of genes were induced by DEHP
at 8hrs but not at any other time. Fourth, there were PPC-
speciﬁc eﬀects. In the rat VPA, WY and PFOA all increased
unique sets of genes. Another set of genes was increased
by DEHP at day 1 but decreased by VPA and CLO. In the
mouse liver WY, DEHP and FENO altered unique subsets of
genes.
The transcriptional changes were, for the most part
dependent on PPARα, as most changes were not observed in
similarly treated PPARα-null mice. The exceptions included
the altered regulation of 6 genes by WY for 5 days, 1
gene by PFOA for 7 days and 41 genes by fenoﬁbrate for
6hrs. Although fenoﬁbrate is considered a PPARα agonist,
there is evidence that other ﬁbrates can activate PPARγ in
transactivation assays [1], and pan-PPAR activation may
contribute to PPARα-independent regulation of a subset of
the PM genes. Overall, these results indicate that both fatty
acid metabolizing and PM genes were dependent on PPARα
for altered regulation by PPC. The PM genes exhibited
unique characteristics in their pattern of expression.6 PPAR Research
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Figure 2: Altered expression of proteome maintenance genes by diverse PPC is predominantly PPARα dependent. Wild-type or PPARα-
null mice were treated with WY, DEHP, PFOA, or FENO for the indicated times. Hepatic mRNA transcripts were assessed using full-
genomeAﬀymetrix arrays.Genes involved in PM including protein chaperones were identiﬁed as described in Section 2.( a )P o s i t i v ec o n t r o l
genes. (b) Expression of all PM genes altered by at least one of the treatments. Genes were clustered using one-dimensional hierarchical
clustering. All genes are found in Supplemental Material. Red: up-regulation; green: down-regulation; black: no change. The intensity
scalesindicate fold-changedue to chemical exposure relative to controls.Abbreviations:WY:WY-14,643;DEHP: di-(2-ethylhexyl)phthalate;
PFOA: perﬂuorooctanoic acid; FENO: fenoﬁbrate.
3.2.Regulationof ProteasomalGenesbyPPC. Ala r gen um ber
of genes encoding components of the proteasome were
altered by WY [16]. We examined the expression of the pro-
teasomalgenes(Psm)aswellasthoseknowntobein volvedin
ubiquitin-dependentproteolysisafterPPCexposure (Figures
3(a) and 3(b)). In both species all of the Psm genes which
exhibited altered regulation were upregulated except those
that are components of the immunoproteasome (i.e., Psmb8
in rats and Psmb8, Psmb9 and Psmb10 in mice). DEHP and
VPA in rats and WY and PFOA in mice altered the largest
number of Psm genes. In contrast, DEHP in mice transiently
altered only a small set of Psm genes. The changes were never
observed earlier than 1 day in rats. DEHP, VPA and PFOA
in rats and WY and PFOA in mice altered subunits of both
the catalytic core (20S proteasome) and the ATP-dependent
regulatory core (19S proteasome), whereas CLO and WY
in rats preferentially altered 20S components. There were a
number of genes that were altered in both species including
Psma1, Psma5, Psma7, Psmb2, Psmb3, Psmb4, Psmb8, Psmc4,
Psmd1, Psmd4, and Psmd13. All of the Psm genes altered by
PPC in mice were PPARα dependent.
In an examination of the ubiquitination machinery, PPC
altered 8 probesets (6 genes) in rat liver and 48 probesets (35
genes) in mouse liver (data not shown; see Supplemenary
Material). None of the rat genes were altered by more
than two PPC and in the mouse liver, only one gene
(Usp38) was altered by three out of the four PPCs. All
but six of the ubiquitination genes were PPARα dependent.PPAR Research 7
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Figure 3: Expressionof the proteasomalgenes in therat and mouseliver after PPC treatment. Proteasomalgeneexpression wasexamined in
the(a)ratliveror(b) mouseliverafterPPCexposure usingthestudiesdescribed inFigures 1and2.Genes whichexhibited altered expression
in at least one of the treatments are shown. Genes are presented in alphabetical order. Many genes were represented by more than one probe
set.
These ﬁndings extend the results from our earlier study and
show that diverse PPCs coordinately alter the expression of
the Psm genes in a PPARα-dependent manner.
3.3. Regulation of Protein Chaperone Genes by PPC. We
examined the expression of protein chaperone genes after
PPC exposure (Figures 4(a) and 4(b)). Almost all of the
chaperone genes were upregulated by PPC in rat liver
and by WY in the mouse liver. There were many genes
that were regulated by more than half of the PPC in rat
liver including Hsp90aa1, Hsp90ab1, Hspa8, Hspb1, Hspd1,
Hspe1, Hspa9, and Hsph1. In the mouse liver most of the
PPC regulated a smaller set of genes including Dnaja2,
Grpel2, Hsp90aa1, Hspa4l, Hspa8, Hspb1, and Hsph1.M a n y
genes were commonly regulated in both species by at least
half of the PPC (Dnaja1, Dnaja2, Hsp90aa1, Hspa1a/b,
Hspa8, Hspb1, Hspd1, Hspe1, Hspa9, and Hsph1). Some
of the changes were transient, exhibiting attenuated or no
regulation after long-term exposure. For WY (Figure 4(b)),
these included Dnaja1, Dnajb1, Dnajb4, Hspa1a, Hspa1b,
Hspa8, Hsph1,a n dHsp90aa1 and for DEHP, these included
Dnaja1, Dnaja2, Dnajc12, Grpel2, Hsp90aa1, Hspb1, and
Hspb8. There were a number of chaperone genes that were
uniquelyregulatedby VPA (Dnaja4, Hspa4), PFOA(Hspa9a-
predicted)o rb o t h( Hspa1b)i nr a tl i v e r .E x p o s u r et oD E H P
in the mouse for 3 days gave a unique pattern of changes in
which Dnaja1, Dnajb1, Dnajb4, Hspa1a, Hspa1b, and Hsph1
were downregulated at 3 days compared to the consistent
up-regulation by the other PPC. Furthermore, three of
these genes (Hspa1a, Hspa1b, Hsph1) were upregulated after
shorter-term exposure. These results indicate that multiple
and possibly competing mechanisms may beregulating these
genesafterDEHPexposure,diﬀerentfromthatofotherPPC.
In the mouse liver, most of the genes required PPARα for8 PPAR Research
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Figure 4: Expression of the protein chaperone genes in the rat and mouse liver after PPC treatment. Protein chaperone gene expression was
examined in the (a) rat liver or (b) mouse liver after PPC exposure using the studies described in Figures 1 and 2. Genes which exhibited
altered expression in at least one of the treatments are shown. Genes are presented in alphabetical order. Many genes were represented by
more than one probe set.
altered expression except for Dnaja3, Grpel2, and Hsp90b1
thatappeared toberegulatedsimilarly by FENOin wild-type
and PPARα-null mice.
3.4.ExpressionofChaperone ProteinsinMouseLiverafterPPC
Exposure. We examined expression of protein chaperones in
protein extracts from livers of mice given ﬁve diﬀerent doses
of WY for 6 days or DEHP at one dose level for 7 days.
Giventhetranscriptional increases inchaperonin-containing
T-complex 1 (Tcp-1) family members Cct3, Cct4, Cct7, and
Cct8 after exposure to PPC in wild-type mice (Supplemental
Material),we also examined the expression of Tcp1η protein.
Dose-dependent increases in Tcp1η, Hsp86, Cyp4A, ACO-A
and Hsp110 were observed in WY-treated wild-type B6C3F1
mice (Figure 5(a)). The chaperones exhibited dissimilar
dose-dependent inductions as TCP1η was induced at lower
doses similar to the direct PPARα targets ACO-A and
Cyp4a, whereas Hsp86 and Hsp110 were induced only at
the higher doses. Induction of Hsp25 and Hsp70 was strain
speciﬁc; induction by WY was observed in SV129 mice [31]PPAR Research 9
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Figure 5: Expression of chaperone proteins after PPC treatment. (a) Protein expression in the livers of mice treated with diﬀerent doses of
WY. B6C3F1 mice were treated with the indicated concentrations of WY in the diet for 6 days. Protein expression was assessed by Westerns
using primary antibodies against the indicated proteins. Blots were quantitated as described in Section 2. (b) Protein expression in livers of
wild-type and PPARα-null mice after exposure to DEHP. Proteins were extracted from the livers of wild-type or PPARα-null mice given 7
consecutive doses of DEHP (1000mg/kg day). There were 3 animals per treatment group. Variability is expressed as standard error of the
mean.MeansandS.E.(n = 3) forwestern datawere calculatedby Student’s t-test. The level ofsigniﬁcancewasset at P ≤ .05andsigniﬁcance
is indicated with ∗.
but not in B6C3F1 mice (data not shown). Like ACO-A and
ACO-B proteins, induction of Tcp1η, Hsp70, Hsp86, and
Hsp110 protein expression was observed after exposure to
DEHP in wild-type but not PPARα-null mice (Figure 5(b)).
These results demonstrate that diverse PPC induce protein
chaperone expression dependent on PPARα.
3.5. Comparison of the Proteome Maintenance Genes Altered
by Chemicals That Activate Other Nuclear Receptors. Many
of the PM genes have been shown to be induced under
conditions of stress leading to the hypothesis that the
response to PPC may be due to activation of a generalized
stress response. If that was thecase,we wouldpredict that the
genes would be altered by other chemicals given at relatively
high doses. To determine the speciﬁcity of the PPC response,
the expression changes of the PM genes were compared
between PPC and chemicals which activate other nuclear
receptors: phenobarbital (PB) which activates CAR and
pregnenolone-16alpha-carbonitrile (PCN) which activates
the pregnane X receptor (PXR). In a published study [29],
P B ,o rP C Nw e r eg i v e nt or a t sa t1 0 0 m g / k g / d a yf o r6 h r s ,
1 day or 5 days. Microarray analysis was performed using
the same microarray platform and analysis procedures as
described above. We compared the PM genes and found that
out of the genes that were altered by PPC, PB or PCN, most
of the genes were uniquely altered by the PPC (Figure 6(a)).
In contrast, only 3 genes were altered by PB and/or PCN
but not any of the PPC. There were 47 overlapping genes
which exhibited for the most part similar expression by the
PPC and PB or PCN (Figure 6(b)). In particular, there was
a group of genes that were consistently upregulated by PB,
PCN and two or more PPC including Ppil3, Psma2, Psma7,
Psmb2, Psmb3, Psmb4, Psmb5, Psmc4, and Psmc5. Due to
their promiscuous induction by most of the chemicals, we
hypothesize thatthesegeneswere alteredduetoageneralized
stress response and not due to activation of a particular
nuclear receptor. However, most of the PM genes that were
altered by PPC formed a unique group that was only altered
by one or more PPC but not by activators of other nuclear
receptors.PPAR Research 11
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Figure 6: Comparison of the expression of the PM genes after exposure to PPARα, CAR and PXR activators. Lists of diﬀerentially regulated
genes were generated after exposure to phenobarbital (PB), pregnenolone-16alpha-carbonitrile (PCN) or the PPC. The expression of the
PM genes (probe sets) were compared between the treatments. (a) Overlap in the PM gene probesets that were altered in one or more of the
three time points after PB or PCN exposure or after 3 or 4 of the 4 PPC treatment groups are shown. (b) The 47 overlapping gene probe sets
were clustered as described above.
4.Discussion
The nuclear receptor PPARα is considered a key factor in
lipid homeostasis. There is increasing evidence that PPARα
plays additional functional roles in the liver by regulating
responses to various chemical and physical stressors [14]. An
agonist of PPARα (WY) regulates responses in the mouse
liver to chemical stress in part by altering expression of genes
involved in proteome maintenance (PM) such as the Hsp
genes involved in protein folding and Psm genes involved
in proteolysis. In this study, we show that other PPARα
activators including diverse hypolipidemic and xenobiotic
compounds also regulate a common set of PM genes in
the rat and mouse liver. These transcriptional changes were,
for the most part dependent on PPARα because most of
the altered genes were altered by PPC but not by chemicals
that activate other nuclear receptors, CAR and PXR. In mice
the changes in the PM genes were observed in wild-type
but not PPARα-null mice. The responsive PM genes did not
exhibit the same transcriptional behavior as genes known
to be direct targets of PPARα (e.g., Acox1 or Cyp4a family
members) in which PPARα binds directly to peroxisome
proliferator response elements (PPRE) in their promoters.
Whilethedirecttargetswere upregulatedearly afterexposure
and remained elevated throughout the duration of the
experiment, the PM genes exhibited a lag before expression12 PPAR Research
changed and in many cases, the changes were transient.
A number of PM genes were identiﬁed that were not
universally regulated by all of the PPC. Discordance in the
expression pattern between the PPC could be explained
in part due to the selection of dose and time which can
both inﬂuence the gene expression results of these studies.
However,ourstudiesindicate thatthe PM genesare a unique
subset of PPARα target genes that appear to be regulated by a
mechanism diﬀerent than fatty acid oxidation genes.
How are the PM genesregulated by PPC throughPPARα?
Given that Hsp gene expression is controlled in part by
heat shock factor 1 (HSF1), one possibility is that the
increases in Hsp gene expression are secondary to increases
in the expression and activity of HSF1. However, we did
not observe changes in HSF1 expression in our transcript
proﬁling studies and earlier studies showed that HSF1 and
HSF2 expression and binding to HSE were not altered by
WY exposure in therat liver[32].To help determinewhether
regulation of Hsp gene expression is direct or indirect, we
examined their promoters and found that only a few genes
possess a putative PPRE(s) (data not shown). The fact that
most oftheHspandPsm genesarenotimmediatelyincreased
by PPC exposure indicates that additional molecular events
are required before induction can occur.
Many Hsp genes may be regulated indirectly through
generalized stress responses especially those that are induced
after exposure to the relatively high doses of the chemicals
used in the animal studies. One of the stress responses that
m a yb ed r i v i n gt h ee x p r e s s i o no ft h eg e n e si si n c r e a s e si n
oxidativestress. There is abundant evidencefor theincreased
expression of chaperone gene expression by oxidative stress
[10, 33]. PPC exposure leads to increases in oxidative stress
and lipid peroxidation mediated through increased activities
of enzymes that generate reactive oxygen species (reviewed
in [2]). Furthermore, as oxidative stress after PPC exposure
is a relatively high dose phenomenon [2], the induction
of Hsp86 and Hsp110 only at high doses is consistent
with an indirect mechanism of induction, possibly through
increases in oxidative stress. Likewise, induction of Psm gene
expression may be an adaptation to decreases in the levels
of functional proteasomes through damage by oxidative
stress. Treatment of cells in vitro with proteasome inhibitors
increased the expression of a broad range of subunits of the
proteasome in diverse species [13, 34] even when less than
50% of the total proteasomal activity was inhibited [13].
Proteasome inhibition resulted in increased expression of
19S and 20S components but decreased expression of Psmb8
[13], a pattern similar to that observed with PPC. Since
direct oxidative modiﬁcation of the catalytic core subunits
of the proteasome inhibits their activities [35], PPC may
be increasing the level of oxidized proteins that inhibit the
proteasome,triggeringcompensatory increasesinPsm genes.
Lastly, the absolute increases in expression of some Hsp
and Psm genes was higher in WY-treated mice nullizygous
for Nrf2, a transcription factor activated by oxidative stress
that regulates genes that dampen oxidative stress. Thus,
in the absence of Nrf2, increased levels of oxidative stress
may have contributed to the greater increases in the PM
genes by WY [16]. Taken together, these results indicate that
PPARα may regulate the PM genes secondary to increases in
oxidative stress. An alternative hypothesis is that PM genes
are induced in response to the demand for folded proteins
underconditionsofincreased proteinsynthesis during active
reprogramming of gene expression coincident with increases
in peroxisomes and smooth endoplasmic reticulum (SER)
and increases in cell number. This hypothesis is consistent
with the fact that a subset of the PM genes were induced by
C A R ,P X Ra sw e l la sP P A R α activators, all of which induce
SER proliferation and hepatocyte proliferation. This would
also help to explain the somewhat transient nature of the
gene expression changes as after acute exposure the liver
reaches a new equilibrium in which hepatocyte proliferation
returns to normal levels. Further experiments are needed to
determine the molecular basis for the induction of the PM
genes.
What might the increased levels of PM proteins be doing
in the liver after WY exposure? Increased levels of PM gene
products might allow tight control of the inducibility of
PPARα. Many nuclear receptors interact with chaperone
proteins including the ones induced by PPC in our studies
[36]. PPARα interacts with Hsp72 [37] and is inhibited
by Hsp90 [38]. PPARα activation is also downregulated by
proteasomal proteolysis [39]. Thus, induction of some PM
genes may dampen the PPARα transcriptional response. Hsp
induction may also help support the increases in protein
synthesis required for liver enlargement including peroxi-
some proliferation after PPC exposure. Increased expression
of TCP1 subunits may be important for proper protein
insertion into the peroxisomal membrane [40]. Increased
expression of Hsp family members has been mechanistically
linked to protection from apoptosis [41, 42] and PPC, at
least under acute exposure conditions, decrease basal levels
of apoptosis [2].
A fundamental question arises as to why PPARα would
have a dual role of regulating both PM genes involved in
stress responses and lipid metabolism genes. The ability of
PPARα to act as a regulator of responses to diﬀerent types
of stressors may have coevolved and become inexorably
linked with the most important stressor mammals face
in the wild, that is, an inadequate or inconsistent food
supply. Periods of starvation or caloric restriction requires
a reprogramming of gene expression to utilize stored fat and
to allow adaptation to new, potentially toxic food sources.
PPARα is a master regulator of the starvation response. Gene
expression changes by fasting [43, 44] or caloric restriction
[14, 17] partly depend on PPARα including genes that
mobilize, transport and catabolize fats. The ability of PPARα
to also regulate genes (e.g., Hsp family members) involved
in suppression of cytotoxicity induced by unfolded proteins
would make teleological sense and may allow increased
resistance to potentially toxic foods animals are forced to eat
when the customary foods are no longer available.
In summary, we used transcript proﬁling to show that
PPARα activated by diverse PPC regulates the expression
of two classes of genes that may be responsible for protec-
tion from chemical-induced oxidative stress: the chaperone
genes involved in protein folding and genes involved in
proteasomal degradation of damaged proteins. Induction ofPPAR Research 13
these potentially protective pathways may provide eﬃcient
means for cells to survive conditions of oxidative stress that
contribute to chronic diseases. Induction of these pathways
through pharmacological means provides opportunities for
protection in a number of settings in which there is
induction of oxidative stress, oxidative damage to proteins,
and increased occurrence of disease.
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